Analytical Data
-
Gene name
SPRED1
- Application
-
Alternative Names
SPRED1;Sprouty-related. EVH1 domain-containing Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7Z699
-
Expression Region
2-444aa
-
AA Sequence
SEETATSDNDNSYARVRAVVMTRDDSSGGWLPLGGSGLSSVTVFKVPHQE ENGCADFFIRGERLRDKMVVLECMLKKDLIYNKVTPTFHHWKIDDKKFGL TFQSPADARAFDRGIRRAIEDISQGCPESKNEAEGADDLQANEEDSSSSL VKDHLFQQETVVTSEPYRSSNIRPSPFEDLNARRVYMQSQANQITFGQPG LDIQSRSMEYVQRQISKECGSLKSQNRVPLKSIRHVSFQDEDEIVRINPR DILIRRYADYRHPDMWKNDLERDDADSSIQFSKPDSKKSDYLYSCGDETK LSSPKDSVVFKTQPSSLKIKKSKRRKEDGERSRCVYCQERFNHEENVRGK CQDAPDPIKRCIYQVSCMLCAESMLYHCMSDSEGDFSDPCSCDTSDDKFC LRWLALVALSFIVPCMCCYVPLRMCHRCGEACGCCGGKHKAAG
-
Molecular Weight
70 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SPRED1 (Sprouty-related EVH1 domain-containing protein 1) is a crucial adaptor protein involved in cellular signaling pathways, particularly those related to the RAS-MAPK (mitogen-activated protein kinase) pathway, which plays a significant role in cell proliferation, differentiation, and survival. Mutations in the SPRED1 gene have been associated with clinical conditions such as Neurofibromatosis type 1 (NF1) and various malignancies, highlighting its importance in cellular signaling and oncology. Research into the recombinant SPRED1 protein has gained prominence as it allows scientists to investigate the functional aspects of SPRED1, including its interactions with other signaling molecules, its role in modulating RAS signaling, and its potential as a therapeutic target. Recombinant SPRED1 protein can be produced using various expression systems, enabling detailed structural and biophysical characterization as well as biological activity assays. These studies may reveal insights into the mechanistic underpinnings of diseases linked to SPRED1 dysregulation and facilitate the development of novel therapeutic strategies aimed at targeting specific pathways influenced by SPRED1. Understanding the role of SPRED1 at the molecular level could provide significant advancements in the fields of cancer research and developmental biology, ultimately contributing to the identification of new biomarkers and therapeutic interventions for conditions associated with RAS signaling dysregulation.
